Zylö Therapeutics is committed to leveraging its innovative Nanopod™ sustained-release drug-delivery platform by working with partners across the Rx-OTC-cosmeceutical spectrum to develop and commercialize unique therapies that address unmet clinical needs.

We are seeking regional or global development partners that are interested in evaluating:

  • a proprietary therapeutic agent of their own, combined with our sustained-release Nanopod™ delivery technology

  • curcumin-releasing Nanopods™ for the treatment of osteoarthritis or other inflammatory conditions

  • Nitric Oxide-releasing Nanopods™ for the treatment of dermatological and other conditions

  • Nitric Oxide-releasing and/or sildenafil-releasing Nanopods™ for the treatment (topically) of Erectile Dysfunction

  • Nitric Oxide-loaded Nanopods™ (which disrupt biofilms) for the treatment of sinusitis or cystic fibrosis

  • Nitric Oxide-loaded Nanopods™ (vasodilatory) for the treatment of Raynaud’s Disease (a vasoconstrictive response)

  • Iron-loaded Nanopods™ for the treatment of iron-deficiency anemia

  • cannabis-releasing Nanopods™ for the treatment of chronic pain, skin manifestations of lupus, muscle spasms, or other indications

  • Nanopods™ that release one or more of the following for any number of possible Rx/OTC/cosmeceutical applications: Lidocaine, Nitric Oxide, curcumin, quercetin, allicin, Vitamin A, Vitamin C, Vitamin E, melanin

  • To discuss potential business development opportunities, please contact us at the following email address: